Thursday, 23 September 2021


Sinovac Biotech files for conditional market authorisation for CoronaVac vaccine

05 February 2021 | News

The vaccine candidate was tested in phase III clinical studies outside of China.

Source credit: Shutterstock

Source credit: Shutterstock

Sinovac Biotech Ltd, a leading provider of biopharmaceutical products in China, announced that it has officially filed for conditional market authorisation for CoronaVac, the COVID-19 vaccine, with China’s National Medical Products Administration (NMPA).

The vaccine candidate was tested in phase III clinical studies outside of China. The preliminary results of the trials demonstrated a good safety profile for the vaccine. Fourteen days after a two-dose vaccination, the efficacy rate meets the standards of the World Health Organization (WHO) and the guiding principles for Clinical Evaluation on Preventive COVID-19 Vaccine (tentative) issued by the NMPA.

This announcement may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the ‘safe harbour’ provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements.

This announcement contains forward-looking information about the Company’s efforts to develop a potential COVID-19 vaccine that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

 

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account